

# Wolbachia-Mediated Antiviral Protection in Drosophila Larvae and Adults following Oral Infection

# Aleksej L. Stevanovic, Pieter A. Arnold, Karyn N. Johnson

School of Biological Sciences, The University of Queensland, Brisbane, Queensland, Australia

Understanding viral dynamics in arthropods is of great importance when designing models to describe how viral spread can influence arthropod populations. The endosymbiotic bacterium *Wolbachia* spp., which is present in up to 40% of all insect species, has the ability to alter viral dynamics in both *Drosophila* spp. and mosquitoes, a feature that in mosquitoes may be utilized to limit spread of important arboviruses. To understand the potential effect of *Wolbachia* on viral dynamics in nature, it is important to consider the impact of natural routes of virus infection on *Wolbachia* antiviral effects. Using adult *Drosophila* strains, we show here that *Drosophila-Wolbachia* associations that have previously been shown to confer antiviral protection following systemic viral infection also confer protection against virus-induced mortality following oral exposure to Drosophila C virus in adults. Interestingly, a different pattern was observed when the same fly lines were challenged with the virus when still larvae. Analysis of the four *Drosophila-Wolbachia* associations that were protective in adults indicated that only the w1118-*w*MelPop association conferred protection in larvae following oral delivery of the virus. Analysis of *Wolbachia* density using quantitative PCR (qPCR) showed that a high *Wolbachia* density was congruent with antiviral protection in both adults and larvae. This study indicates that *Wolbachia*-mediated protection may vary between larval and adult stages of a given *Wolbachia*-host combination and that the variations in susceptibility by life stage correspond with *Wolbachia* density. The differences in the outcome of virus infection are likely to influence viral dynamics in *Wolbachia*-infected insect populations in nature and could also have important implications for the transmission of arboviruses in mosquito populations.

A rthropods harbor a wide range of viruses that can be transmitted between individuals or populations of the same species or can bridge the interspecies gap to infect plants or other animals. The outcome of viral infections can be modulated by tripartite interactions between arthropods, viruses, and bacteria (1). One such interaction is the tripartite interaction between insects, viruses, and the endosymbyotic bacterium *Wolbachia pipientis*.

Wolbachia spp. have gained much attention due to the antiviral effects they confer to their host. The impact of Wolbachia spp. on virus infection was first described in the Drosophila melanogaster host, where it was shown to protect against mortality induced by diverse viruses, including Drosophila C virus (DCV), cricket paralysis virus, and Flock House virus (2, 3). Since that discovery, Wolbachia-mediated antiviral effects have been demonstrated in a number of insect hosts and are being investigated as a way of limiting spread of arboviruses (reviewed in references 1, 4, 5, and 6). Notably, Wolbachia-mediated antiviral effects have been demonstrated in adult mosquitoes artificially infected with Wolbachia; in mosquitoes, Wolbachia can interfere with accumulation and transmission of important human pathogens, including dengue and Chikungunya viruses (7-17). While in many cases Wolbachia confers antiviral effects to its host organism, in some cases the presence of Wolbachia can enhance viral susceptibility (18-23). The impact of the presence of Wolbachia on virus infection can include two main effects: (i) interference with viral replication/ accumulation, and/or (ii) protection against virus-induced mortality. In mosquitoes, Wolbachia interferes with viral replication/ accumulation, while in Drosophila, Wolbachia can interfere with viral replication/accumulation and/or protect flies from virus-induced mortality. In this paper, we focus on the effect of Wolbachia on the survival of the host, and we define protection as a reduction/delay in virus-induced mortality.

The mechanisms involved in *Wolbachia*-mediated antiviral effects have not yet been fully elucidated. There is some evidence that microRNAs (24, 25), competition for host-derived resources (26), and elevated reactive oxygen species (27, 28) may influence antiviral effects. *Drosophila-Wolbachia* associations can be subdivided into two groups: protective and nonprotective. The *Drosophila-Wolbachia* pairings CO-wAu, DSR-wRi, w1118-wMel, and the overreplicating and life-shortening w1118-wMelPop association all show a delay in DCV-induced mortality when DCV is injected into adult flies, while the N7NO-wNo and DSH-wHa combinations did not (2, 3, 11, 29). A feature that all protective *Wolbachia* strains share is high density within their respective host organism, indicating that high *Wolbachia* density may serve as a prerequisite for antiviral protection (7, 12, 29–34).

Wolbachia is estimated to infect 40% of all insects (35); therefore, the effect it exerts on natural viral dynamics could be pronounced. The understanding of natural tripartite *Drosophila*-virus-*Wolbachia* interactions is very limited at present, partially due to a lack of a method for orally delivering the virus. Recently, three methods for oral infection of larvae and adults were described, and these will allow us to study the effects of the

Received 1 September 2015 Accepted 16 September 2015

Accepted manuscript posted online 25 September 2015

Citation Stevanovic AL, Arnold PA, Johnson KN. 2015. *Wolbachia*-mediated antiviral protection in *Drosophila* larvae and adults following oral infection. Appl Environ Microbiol 81:8215–8223. doi:10.1128/AEM.02841-15.

Editor: H. Goodrich-Blair

Address correspondence to Karyn N. Johnson, karynj@uq.edu.au. Copyright © 2015, American Society for Microbiology. All Rights Reserved. oral route of infection on antiviral protection mechanisms in *Drosophila* (36–38).

To investigate the effects of Wolbachia on virus-induced mortality following oral infection, we used DCV, a natural Drosophila pathogen and the most widely studied Drosophila virus (39). DCV is a positive-sense RNA virus that belongs to the Dicistroviridae family (40). When injected into flies, DCV is pathogenic, causing mortality within 4 to 6 days postinjection (41). Injection of DCV is a useful method to study *Wolbachia*-DCV interactions; however, injection bypasses the fly's natural immune barriers present within the midgut and can cause a differential immune response compared to exposure via virus feeding alone (37). DCV infection by ingestion is less pathogenic than by injection (36, 37)and represents a more natural Drosophila-DCV interaction. While Wolbachia-mediated protection has been extensively studied in adult flies following a systemic infection, it is not yet clear whether the Drosophila-Wolbachia associations that are protective for virus-induced host mortality following viral injection also exhibit a similar protective characteristic following the oral route of infection. Ingestion of infected cadavers is thought to be one of the mechanisms through which DCV transmission occurs naturally within an insect population (42); therefore, Wolbachia-mediated antiviral protection following the oral route of infection could have a direct impact on viral transmission and maintenance of the virus within a population.

Understanding the potential of Wolbachia to affect viral dynamics in natural populations will be facilitated by insights into the impact of antiviral protection on susceptibility throughout the life cycle of the host, following exposure via a natural route of infection. Both Drosophila and mosquitoes are holometabolous insects, as they undergo metamorphosis between the larval and adult stages. A wide range of genes coordinate the disintegration of larval structures, where some larval organs are histolyzed and major new growth takes place, altering the morphology and in some cases pathogen susceptibility (43-45). Pathogen susceptibility is often age or life stage dependent and can have a large effect on population dynamics, viral spread, and maintenance of the virus within the population (45-48). Studies focusing on the antiviral effects of Wolbachia have to date been conducted solely on adult flies and mosquitoes, without consideration of other developmental stages.

Here, we investigated the effect of *Wolbachia* on virus-induced mortality of *Drosophila* larvae and adults following oral challenge with DCV. By using four *Drosophila-Wolbachia* associations that have previously been shown to be protective for adult insects following viral injection, we show that the *Drosophila-Wolbachia* associations that are protective against virus-induced mortality following injection are also protective following oral infection of adults. In contrast, *Wolbachia* protection at the adult stages is not indicative of protection at larval stages, as only one out of four *Drosophila-Wolbachia* associations that were protective at the adult stage showed protection at the larval stage.

#### MATERIALS AND METHODS

**Drosophila and Wolbachia.** Two Drosophila melanogaster and three Drosophila simulans fly lines were reared on a standard cornmeal medium at a constant temperature of 25°C with a 12-hour light/dark cycle. Paired populations of flies were used that either contained Wolbachia (w1118-wMel, w1118-wMelPop, N7NO-wNo, DSR-wRi, and Co-wAu) or had been cured of Wolbachia by tetracycline treatment (w1118-T, N7NO-T, DSR-T, and CO-T); flies were maintained on a standard cornmeal medium for at least five generations before use. Gut flora was reconstituted and normalized across fly lines by using standardized methods (31). Briefly, *Drosophila* embryos were transferred to vials containing 150  $\mu$ l of a bacterial inoculum, which was prepared by adding 2 g of 10-day-old food containing w1118-*w*MelPop flies to 5 ml of sterile water and strained through a fine sterile mesh to remove larvae and embryos. The newly treated flies were checked for the presence of *Wolbachia* by using PCR, to make sure that no cross-contamination had occurred.

**Virus.** Plaque-purified DCV isolate EB (49, 50) was propagated and purified from Schneider's *Drosophila* line 2 cells (51), and virus titers were determined based on the 50% tissue culture infective dose (TCID<sub>50</sub>), as described previously (29, 49).

**DNA extraction.** Thirty 0- to 4-h-old larvae or 10 newly emerged male adult flies were pooled to perform DNA extraction. The flies were homogenized using a pestle in 180  $\mu$ l of extraction buffer and 20  $\mu$ l of proteinase K. The DNeasy blood and tissue kit (Qiagen) was used to extract the DNA as per the manufacturer's protocol. Three replicates on independent cohorts were performed for each treatment.

Quantitative PCR. The abundance of Wolbachia was assessed by quantitative PCR (qPCR) to determine the abundance of the Wolbachia surface protein gene (wsp) relative to that of either the D. melanogaster RrpL32 or D. simulans Act5C genes. Platinum SYBR green qPCR Super-Mix-UDG (Invitrogen) was used per the manufacturer's instruction using the wsp-specific primer pair 5'-GCATTTGGTTAYAAAATGGACGA-3' and 5'-GGAGTGATAGGCATATCTTCAAT-3' (producing a 185-bp PCR product) (29), RpL32-specific primers 5'-GACGCTTCAAGGGAC AGTATCTG-3' and 5'-AAACGCGGTTCTGCATGAG-3' (producing a 141-bp PCR product) (49), and Act5C-specific primers 5'-GACGAAGA AGTTGCTGCTCTGGTTG-3' and 5'-TGAGGATACCACGCTTGCTCT GC-3' (producing a 192-bp PCR product) (30). The Rotor-Gene 6000 thermal cycler (Corbett Life Sciences, Qiagen) was used with the following profile: 95°C for 2 min, followed by 40 cycles of 95°C for 10 s, 52°C for 10 s, and 72°C for 20 s. This was followed by a standard melt analysis to assess the specificity of the amplified product. Two technical replicates (separate qPCRs on the same DNA) were performed for each sample (with a third performed where necessary), and DNA extracted from flies without Wolbachia was used as a negative control. Mean normalized wsp:RpL32 DNA ratios were calculated using qGENE software (52), and statistical analysis included a two-tailed Student's t test to compare differences of the means.

Survival bioassay. Virus for larval and adult feeding assays was prepared by injecting flies with either 5,000 infectious units (IU) of DCV or an equivalent volume of phosphate-buffered saline (PBS), which acted as a control. Live flies were collected at 4 days postinjection and stored at  $-20^{\circ}$ C until further use. Thirty PBS- or DCV-injected flies were pooled and homogenized in 300 µl of PBS, and the supernatant was filter sterilized using a Millex GV 22-µm filter (Merck Millipore). Homogenates prepared in this way were used for both adult and larval bioassays. The titers for DCV-injected fly homogenates were measured on four occasions and ranged between  $4.4 \times 10^{10}$  and  $2 \times 10^{11}$  IU/ml.

For adult infections, a modified version of a previously described method was used (37). A mix (250- $\mu$ l volume) containing 75% fly homogenate (DCV or PBS treated, as described above) and 25% dry yeast was applied to a 1.5- by 1.5-cm filter paper and placed in a vial containing 10 4- to 7-day-old male flies. Flies were incubated with the medium for 24 h at 25°C with high humidity to prevent the food from drying out. Following this period, the flies were transferred to standard cornmeal medium, and mortality was scored daily for 15 days. Three replicates of independent cohorts were performed for each treatment.

Larval infections were performed by spreading DCV- or mockinfected fly homogenates onto petri dishes containing 10 ml of standard cornmeal medium (36). One hundred eggs were collected for each treatment on a wet piece of sterile filter paper and transferred

Wolbachia Antiviral Protection in Larvae and Adults

onto petri dishes containing homogenates from either PBS- or DCVinjected flies. Larvae were maintained on the treatment medium until adult emergence, and they were counted 3 days postemergence. Eggto-adult survival was determined as the proportion of adults postemergence relative to the initial number of eggs at the start of the treatment, and each survival bioassay was replicated 3 times with independent cohorts of insects.

Statistical analysis of the survival bioassay results. We used generalized linear mixed-effects regression (GLMER) models based on a binomial distribution to examine the effect of feeding treatment and coinfection on the mortality of five D. melanogaster and D. simulans larvae, and we employed the lme4 R package in R 2.15.3 (53) (R Foundation for Statistical Computing, Vienna, Austria). The mortality response, as the binomial count of flies that survived or died for each line, was determined by fitting the feeding treatment (PBS or DCV) and coinfection treatment (absence of Wolbachia [-wol] or with a Wolbachia strain), as well as the interaction between the two factors. The interaction term compared across the mortality values of each of the feeding treatments across the absence (-wol) or presence (+ indicated Wolbachia strain) of Wolbachia. Each model included an experimental replicate as a random factor for analysis of the replicate variance component in each model. For adult survival bioassays, the survival curves were compared using Kaplan-Meier analysis and log rank statistics within the GraphPad Prism program.

### RESULTS

Wolbachia protection in adult flies following oral challenge with DCV. Initially, we tested the protective effects of the Wolbachia strain wAu in a CO fly background (CO-wAu) due to a strong antiviral protection observed previously following systemic DCV infection (29). Wolbachia-free CO flies challenged with DCV by oral infection showed 40% mortality within 15 days postfeeding. In contrast, CO-wAu flies showed a significant reduction in mortality during the same time period, to 7% (Fig. 1A; Kaplan-Meyer analysis, P < 0.05). We investigated an additional three Drosophila-Wolbachia associations, DSR-wRi, w1118-wMel, and w1118wMelPop, all of which have previously been shown to confer protection against DCV-induced mortality in adult flies following a systemic infection (3, 29, 49), and the results indicated that all three Drosophila-Wolbachia associations conferred protection against DCV-induced mortality following the oral route of infection (Fig. 1B, D, and E; Kaplan-Meyer analysis, P < 0.05). Because not all Drosophila-Wolbachia associations protect against systemic viral infections, we tested a nonprotective association, N7NOwNo, to see whether protection would occur following oral virus challenge (29). Feeding the nonprotective N7NO-wNo flies with DCV led to a nonsignificant difference in virus-induced mortality compared to Wolbachia-free flies (Fig. 1C; Kaplan-Meyer analysis, P > 0.05). Taken together, these results indicate that *Wolbachia*mediated protection against virus-induced mortality in adults infected through the oral route was consistent with what was previously reported following injection of virus.

*Wolbachia* protection in larvae following oral challenge with DCV. To determine whether exposure to *Wolbachia* sp. protects larvae from virus-induced mortality, we orally challenged COwAu larvae with DCV. We found that in *Wolbachia*-free flies, larvum-to-adult mortality increased from about 37% in mock-infected flies to about 46% in DCV-infected flies and that the presence of *Wolbachia* had no significant effect on DCV-induced mortality (Fig. 2A and Table 1). This suggests that the *Wolbachia* strain wAu may not protect its host against DCV-induced mortality following this route of infection at the larval developmental stages.

As no protection was observed in CO-wAu larvae, we then investigated whether the lack of protection was specific to this *Drosophila-Wolbachia* association. We investigated other protective *Drosophila-Wolbachia* associations, DSR-wRi and w1118wMel, and one nonprotective association, N7NO-wNo. None of these associations showed a significant difference in DCV-induced mortality between larvae with and without *Wolbachia* (Fig. 2B to D and Table 1), suggesting that the lack of *Wolbachia*-mediated protection at the larval stages is not confined to CO-wAu flies.

The *Wolbachia* strain *w*MelPop has a strong protective effect in both adult flies and mosquitoes, so we investigated whether w1118-*w*MelPop larvae exhibited a protective phenotype. In this *Drosophila-Wolbachia* association, there was a statistically significant difference in DCV-induced mortality between flies with and without *Wolbachia* (25% and 37% mortality, respectively) (Fig. 2E and Table 1). Unlike the other *Drosophila-Wolbachia* associations, *w*MelPop provided complete protection against DCV-induced mortality (Fig. 2E). Because the ability to confer antiviral effects is strongly associated with *Wolbachia* density in adult flies and mosquitoes and because *w*MelPop is known to be an overreplicative strain, we investigated whether the observed differences in *Wolbachia* densities.

Wolbachia densities. Wolbachia densities have previously been determined in adults but not in larvae for different Drosophila-Wolbachia associations. Using qPCR, we determined Wolbachia densities at both the larval and adult stages for all five Drosophila-Wolbachia associations used in this study (Fig. 3). In adults, the densities of the protective Wolbachia strains wAu, wRi, wMel, and wMelPop were significantly higher than that of the nonprotective wNo strain, providing an association between Wolbachia density and protection. In contrast, Wolbachia strains wAu, wRi, and wMel showed lower abundance at the larval stage than at the adult stage (two-tailed Student's *t* test, P < 0.05) (Fig. 3A and B), while the Wolbachia strain wMelPop showed high densities at both the larval and adult stages (Fig. 3A). Wolbachia density in the nonprotective N7NO-wNo larvae remained lower than in either the *w*Ri- or *w*Au-treated insects at both developmental stages (Fig. 3B), consistent with a lack of protection.

## DISCUSSION

The importance of the route of pathogen entry on the outcome of infection has been well-documented following bacterial infections in *Drosophila*. Injecting bacteria into the hemocoel induces a systemic immune response (54–57), while oral infections often lead to localized immune induction in the gut, often making the bacteria less pathogenic (58–60). A recent paper that showed the involvement of the Toll immune pathway in mediating resistance to oral viral infection with DCV, Flock House virus, cricket paralysis virus, or Nora virus, however, showed no influence of the viral exposure pathway following a systemic bacterial infection (37), indicating that the route of viral entry can have an effect on the host's response to viral infection.

We used a natural route of DCV infection, oral feeding, to investigate the effect of *Wolbachia* on protection against virusinduced mortality, in order to determine whether *Wolbachia*-mediated protection is confined to systemic viral infections in *Dro*-



**FIG 1** Survival of adult flies following oral challenge with DCV. Each fly strain contained a *Wolbachia* strain (+*wol*) or was tetracycline treated to remove *Wolbachia* (-*wol*). Adult flies were exposed to either homogenates from DCV-infected or mock-infected (PBS) flies for 24 h before being transferred to vials containing standard commeal medium. Survival of flies is shown from 3 biological replicates of 10 flies (or from 1 replicate of 10 flies for PBS controls). Statistically significant differences in survival were determined by using the log rank test on Kaplan-Meier curves.

*sophila*. By examining *Wolbachia*-mediated protection in adult flies across four *Drosophila-Wolbachia* associations that had previously been shown to be protective following systemic bacterial infection, we found that oral DCV infections led to a reduction in virus-induced mortality in adult flies infected with *Wolbachia* compared to *Wolbachia*-free flies (Fig. 1). These findings are consistent with a recently published report (37) and support the idea that *Wolbachia*-mediated protection extends beyond systemic viral infections and could be used in future experiments to better understand the effects of *Wolbachia* on viral dynamics in natural insect populations.

While in adults the *Wolbachia*-mediated reduction in virusinduced mortality is comparable between systemically and orally infected flies, the same is not always true in larvae. Of the four



Downloaded from http://aem.asm.org/ on November 16, 2015 by UQ Library

**FIG 2** The impact of *Wolbachia* on virus-induced mortality in DCV-infected *Drosophila* larvae. Each fly line was exposed to a different *Wolbachia* strain or was tetracycline treated to remove *Wolbachia* (-wol), as indicated on the *x* axis. Larvae were exposed to homogenates from either DCV-infected or mock-infected (PBS) flies. Graphs display means and standard errors from three replicates with 100 individuals per fly strain. \*, significant interaction (P < 0.05) between the feeding treatment and presence or absence of *Wolbachia* for mortality.

Drosophila-Wolbachia associations that showed protection following DCV infection in adults, only the w1118-wMelPop flies showed protection against DCV-induced mortality during the larval stages (Fig. 2E). These results suggest that Wolbachia-mediated protection may vary between different life stages of the same Drosophila-Wolbachia association, although it is possible that the amounts of virus ingested by larvae and adults are different. Since Wolbachia density has previously been shown to be important for mediating antiviral effects, we measured Wolbachia density in adults and found that there was congruence between Wolbachia density and protection against DCV-induced mortality following the oral route of infection. Similarly to adults, *Wolbachia*-protection in larvae was associated with *Wolbachia* density, however interestingly high *Wolbachia* density was only observed in w1118wMelPop larvae, which was also the only association to show protection against DCV-induced mortality at the larval stages. The wMelPop strain causes a life-shortening phenotype and is present in relatively high densities in both mosquitoes and *Drosophila* (7, 61–63). The relatively high density and the life-shortening effects of the wMelPop strain have been reported to be due to the high copy number of 8 *Wolbachia* genes referred as the Octomom region (31, 62). It remains to be seen whether other strains will be

$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Drosophila line and basis of	Parameter			
CO         Intercept $-0.147$ $0.116$ $-1.269$ $0.204$ Feeding treatments $-0.357$ $0.166$ $-2.147$ $<0.05$ Wolbachia treatments $-0.081$ $0.164$ $-0.492$ $0.623$ Treatment interaction $-0.081$ $0.235$ $0.343$ $0.731$ Replicate variance $0$ $0$ $0$ $0$ component $0.067$ $0.164$ $0.409$ $0.683$ Treatment interaction $-0.052$ $0.237$ $-0.219$ $0.827$ Replicate variance $2.4 \times 10^{-11}$ $4.8 \times 10^{-6}$ $0.296$ $0.05$ N7NO         Intercept $-0.619$ $0.121$ $-5.114$ $<0.0001$ Feeding treatments $-0.41$ $0.178$ $-2.296$ $<0.05$ Wolbachia treatments $-0.619$ $0.121$ $-5.114$ $<0.0001$ Feeding treatments $-0.619$ $0.121$ $-5.114$ $<0.0001$ Wolbachia treatments $-0.619$ $0.17$ $0.341$ $0$	analysis	estimate	SE	Z score	P value
$\begin{array}{c ccccc} Intercept & -0.147 & 0.116 & -1.269 & 0.204 \\ Feeding treatments & -0.357 & 0.166 & -2.147 & <0.05 \\ \hline Wolbachia treatments & -0.081 & 0.164 & -0.492 & 0.623 \\ Treatment interaction & -0.081 & 0.235 & 0.343 & 0.731 \\ \hline Replicate variance & 0 & 0 \\ \hline component & & & & & & & & & & & & & & & & & & &$	CO				
Feeding treatments $-0.357$ $0.166$ $-2.147$ $<0.05$ Wolbachia treatments $-0.081$ $0.164$ $-0.492$ $0.623$ Treatment interaction $-0.081$ $0.235$ $0.343$ $0.731$ Replicate variance $0$ $0$ $0$ $0$ component $0$ $0$ $0$ $0$ DSR       Intercept $-0.134$ $0.116$ $-1.154$ $0.249$ Feeding treatments $-0.53$ $0.168$ $-3.152$ $<0.01$ Wolbachia treatments $-0.052$ $0.237$ $-0.219$ $0.827$ Replicate variance $2.4 \times 10^{-11}$ $4.8 \times 10^{-6}$ $0.827$ N7NO       Intercept $-0.619$ $0.121$ $-5.114$ $<0.0001$ Feeding treatments $-0.41$ $0.178$ $-2.296$ $<0.05$ Wolbachia treatments $-0.182$ $0.254$ $-0.717$ $0.474$ Replicate variance $-0.545$ $0.178$ $-3.062$ $<0.01$ Will8       Intercept $-0.563$ $0.179$ $-3.154$ $<0.01$ <td>Intercept</td> <td>-0.147</td> <td>0.116</td> <td>-1.269</td> <td>0.204</td>	Intercept	-0.147	0.116	-1.269	0.204
Wolbachia treatments $-0.081$ $0.164$ $-0.492$ $0.623$ Treatment interaction $-0.081$ $0.235$ $0.343$ $0.731$ Replicate variance $0$ $0$ $0$ component $-0.134$ $0.116$ $-1.154$ $0.249$ Feeding treatments $-0.53$ $0.168$ $-3.152$ $<0.01$ Wolbachia treatments $-0.052$ $0.237$ $-0.219$ $0.827$ Replicate variance $2.4 \times 10^{-11}$ $4.8 \times 10^{-6}$ $-0.219$ $0.827$ N7NO       Intercept $-0.619$ $0.121$ $-5.114$ $<0.0001$ Feeding treatments $-0.41$ $0.178$ $-2.296$ $<0.05$ Wolbachia treatments $-0.619$ $0.254$ $-0.717$ $0.474$ Replicate variance $0.7 \times 10^{-15}$ $9.8 \times 10^{-8}$ $-0.717$ $0.474$ W1118       Intercept $-0.518$ $0.119$ $-4.339$ $<0.0001$ Feeding treatments $-0.563$ $0.179$ $-3.154$ $<0.01$ Will8       Intercept $-0.504$ $0.119$	Feeding treatments	-0.357	0.166	-2.147	< 0.05
$\begin{array}{c} \mbox{Treatment interaction} & -0.081 & 0.235 & 0.343 & 0.731 \\ \mbox{Replicate variance} & 0 & 0 \\ \mbox{SR} & & & & & & & & & & & & & & & & & & &$	Wolbachia treatments	-0.081	0.164	-0.492	0.623
Replicate variance component00DSR Intercept $-0.134$ $0.116$ $-0.53$ $-1.154$ $0.249$ $-0.53$ Feeding treatments Wolbachia treatments $0.067$ $0.164$ $0.409$ $0.683$ $-0.219$ Treatment interaction component $-0.052$ $0.237$ $-0.219$ $-0.219$ $0.827$ $-0.219$ N7NO Intercept Feeding treatments wolbachia treatments ment interaction Replicate variance component $-0.619$ $0.121$ $-5.114$ $-5.114$ $<0.0001$ N7NO Intercept Feeding treatments wolbachia treatments component $-0.619$ $0.121$ $-5.114$ $-5.114$ $<0.0001$ N7NO Intercept Feeding treatments component $-0.619$ $0.121$ $-5.114$ $-0.296$ $<0.051$ N7NO Intercept Feeding treatments component $-0.619$ $0.121$ $-5.114$ $-0.171$ $0.341$ $0.733$ $-0.717$ N7NO Replicate variance component $-0.518$ $0.119$ $-4.339$ $<0.0001$ $-3.154$ N118 Intercept component $-0.504$ $0.119$ $-4.228$ $<0.001$ $-4.228$ w1118 Intercept reatments component $-0.504$ $0.119$ $-4.228$ $<0.0001$ $-4.228$ w1118 Intercept Feeding treatments component $-0.504$ $0.119$ $-4.228$ $<0.0001$ $-4.228$ w1118 Intercept Feeding treatments $-0.631$ $0.18$ $-3.51$ $<0.001$ $-3.51$ W1118 Intercept Feeding treatments $-0.631$ $0.18$ $-3.51$ $<0.001$ $-3.531$	Treatment interaction	-0.081	0.235	0.343	0.731
$\begin{tabular}{ c c c c c c } \hline component \\ \hline DSR & & & & & & & & & & & & & & & & & & &$	Replicate variance	0	0		
DSR Intercept $-0.134$ $0.116$ $-1.154$ $0.249$ Feeding treatments $0.067$ $0.164$ $0.409$ $0.683$ Treatment interaction $-0.052$ $0.237$ $-0.219$ $0.827$ Replicate variance $2.4 \times 10^{-11}$ $4.8 \times 10^{-6}$ N7NO Intercept $-0.619$ $0.121$ $-5.114$ <0.0001 Feeding treatments $0.058$ $0.17$ $0.341$ $0.733$ Treatment interaction $-0.182$ $0.254$ $-0.717$ $0.474$ Replicate variance $9.7 \times 10^{-15}$ $9.8 \times 10^{-8}$ will18 Intercept $-0.518$ $0.119$ $-4.339$ <0.0001 Feeding treatments $-0.563$ $0.179$ $-3.154$ <0.01 Treatment interaction $0.649$ $0.257$ $2.522$ <0.05 Wolbachia treatments $-0.563$ $0.179$ $-3.154$ <0.01 Treatment interaction $0.649$ $0.257$ $2.522$ <0.05 Weilbachia treatments $-0.563$ $0.179$ $-3.154$ <0.01 Willa Intercept $-0.504$ $0.119$ $-4.228$ <0.0001 Feeding treatments $-0.631$ $0.18$ $-3.51$ <0.001 Willa Intercept $-0.504$ $0.119$ $-4.228$ <0.0001 Feeding treatments $-0.631$ $0.18$ $-3.51$ <0.001 Feeding treatments $-0.631$ $0.18$ $-3.51$ <0.001 Wolbachia treatments $-0.101$ $0.17$ $-0.594$ $0.553$ Treatment interaction $0.137$ $0.254$ $0.537$ $0.591$	component				
DSR       -0.134       0.116       -1.154       0.249         Feeding treatments       -0.53       0.168       -3.152       <0.01	DCD				
Intercept $-0.134$ $0.116$ $-1.154$ $0.249$ Feeding treatments $-0.53$ $0.168$ $-3.152$ $<0.01$ Wolbachia treatments $0.067$ $0.164$ $0.409$ $0.683$ Treatment interaction $-0.052$ $0.237$ $-0.219$ $0.827$ Replicate variance $2.4 \times 10^{-11}$ $4.8 \times 10^{-6}$ $0.237$ $-0.219$ $0.827$ N7NO       Intercept $-0.619$ $0.121$ $-5.114$ $<0.0001$ Feeding treatments $-0.41$ $0.178$ $-2.296$ $<0.05$ Wolbachia treatments $0.058$ $0.17$ $0.341$ $0.733$ Treatment interaction $-0.182$ $0.254$ $-0.717$ $0.474$ Replicate variance $9.7 \times 10^{-15}$ $9.8 \times 10^{-8}$ $-3.062$ $<0.01$ Will18       Intercept $-0.545$ $0.178$ $-3.062$ $<0.01$ Weblachia treatments $-0.563$ $0.179$ $-3.154$ $<0.01$ Treatment interaction $0.649$ $0.257$ $2.522$ $<0.05$ Replicate variance	DSR	0.124	0.116	1 154	0.240
Freeding freatments $-0.53$ $0.168$ $-3.152$ $<0.01$ Wolbachia treatments $0.067$ $0.164$ $0.409$ $0.683$ Treatment interaction $-0.052$ $0.237$ $-0.219$ $0.827$ Replicate variance $2.4 \times 10^{-11}$ $4.8 \times 10^{-6}$ $-0.219$ $0.827$ N7NO       Intercept $-0.619$ $0.121$ $-5.114$ $<0.0001$ Feeding treatments $-0.41$ $0.178$ $-2.296$ $<0.05$ Wolbachia treatments $0.058$ $0.17$ $0.341$ $0.733$ Treatment interaction $-0.182$ $0.254$ $-0.717$ $0.474$ Replicate variance $9.7 \times 10^{-15}$ $9.8 \times 10^{-8}$ $-3.062$ $<0.01$ Will18       Intercept $-0.545$ $0.178$ $-3.062$ $<0.01$ Treatment interaction $0.649$ $0.257$ $2.522$ $<0.05$ Replicate variance $5.9 \times 10^{-12}$ $2.4 \times 10^{-6}$ $<0.05$ will18       Intercept $-0.504$ $0.119$ $-4.228$ $<0.0001$ Welbachia treatments       <	Intercept	-0.134	0.116	-1.154	0.249
Woldachia treatments $0.067$ $0.164$ $0.409$ $0.685$ Treatment interaction $-0.052$ $0.237$ $-0.219$ $0.827$ Replicate variance $2.4 \times 10^{-11}$ $4.8 \times 10^{-6}$ $-0.219$ $0.827$ N7NO       Intercept $-0.619$ $0.121$ $-5.114$ $<0.0001$ Feeding treatments $-0.41$ $0.178$ $-2.296$ $<0.05$ Wolbachia treatments $0.058$ $0.17$ $0.341$ $0.733$ Treatment interaction $-0.182$ $0.254$ $-0.717$ $0.474$ Replicate variance $9.7 \times 10^{-15}$ $9.8 \times 10^{-8}$ $-0.612$ $<0.001$ Feeding treatments $-0.545$ $0.178$ $-3.062$ $<0.01$ Wabbachia treatments $-0.563$ $0.179$ $-3.154$ $<0.01$ Treatment interaction $0.649$ $0.257$ $2.522$ $<0.05$ Replicate variance $5.9 \times 10^{-12}$ $2.4 \times 10^{-6}$ $<0.058$ $<0.001$ w1118       Intercept $-0.631$ $0.18$ $-3.51$ $<0.001$ Willae	Feeding treatments	-0.55	0.168	-5.152	< 0.01
Iteratment interaction Replicate variance $-0.052$ $0.257$ $-0.219$ $0.827$ Replicate variance component $2.4 \times 10^{-11}$ $4.8 \times 10^{-6}$ $-0.219$ $0.827$ N7NO Intercept Feeding treatments $-0.619$ $0.121$ $-5.114$ $<0.0001$ Feeding treatments $-0.41$ $0.178$ $-2.296$ $<0.05$ Wolbachia treatments $0.058$ $0.17$ $0.341$ $0.733$ Treatment interaction component $-0.182$ $0.254$ $-0.717$ $0.474$ w1118       Intercept $-0.518$ $0.119$ $-4.339$ $<0.0001$ Feeding treatments $-0.563$ $0.179$ $-3.154$ $<0.01$ Wilbachia treatments $-0.563$ $0.179$ $-3.154$ $<0.01$ Treatment interaction component $0.649$ $0.257$ $2.522$ $<0.05$ w1118       Intercept $-0.504$ $0.119$ $-4.228$ $<0.0001$ w1118       Intercept $-0.631$ $0.18$ $-3.51$ $<0.001$ Wolbachia treatments $-0.0101$ $0.17$ $-0.594$ $0.553$	<i>Wolbachia</i> treatments	0.067	0.164	0.409	0.685
Replicate variance $2.4 \times 10^{-4.8 \times 10^{-4.8 \times 10^{-10}}}$ component $2.4 \times 10^{-4.8 \times 10^{-10}}$ N7NO       Intercept $-0.619$ $0.121$ $-5.114$ $<0.0001$ Feeding treatments $-0.41$ $0.178$ $-2.296$ $<0.05$ Wolbachia treatments $0.058$ $0.17$ $0.341$ $0.733$ Treatment interaction $-0.182$ $0.254$ $-0.717$ $0.474$ Replicate variance $9.7 \times 10^{-15}$ $9.8 \times 10^{-8}$ $0.0001$ Feeding treatments $-0.545$ $0.178$ $-3.062$ $<0.01$ Will8       Intercept $-0.563$ $0.179$ $-3.154$ $<0.01$ Treatment interaction $0.649$ $0.257$ $2.522$ $<0.05$ Replicate variance $5.9 \times 10^{-12}$ $2.4 \times 10^{-6}$ $<0.05$ w1118       Intercept $-0.504$ $0.119$ $-4.228$ $<0.0001$ Feeding treatments $-0.631$ $0.18$ $-3.51$ $<0.001$ Will8       Intercept $-0.631$ $0.18$ $-3.51$ $<0.001$ Wolbachia treatme	I reatment interaction	-0.052	0.237	-0.219	0.827
N7NO         Intercept $-0.619$ $0.121$ $-5.114$ $<0.0001$ Feeding treatments $-0.41$ $0.178$ $-2.296$ $<0.05$ Wolbachia treatments $0.058$ $0.17$ $0.341$ $0.733$ Treatment interaction $-0.182$ $0.254$ $-0.717$ $0.474$ Replicate variance $9.7 \times 10^{-15}$ $9.8 \times 10^{-8}$ $0.717$ $0.474$ w1118       Intercept $-0.518$ $0.119$ $-4.339$ $<0.0001$ Feeding treatments $-0.545$ $0.178$ $-3.062$ $<0.01$ Wolbachia treatments $-0.563$ $0.179$ $-3.154$ $<0.01$ Treatment interaction $0.649$ $0.257$ $2.522$ $<0.05$ Replicate variance $5.9 \times 10^{-12}$ $2.4 \times 10^{-6}$ $<118$ w1118       Intercept $-0.504$ $0.119$ $-4.228$ $<0.0001$ Feeding treatments $-0.631$ $0.18$ $-3.51$ $<0.001$ Willabachia treatments $-0.101$ $0.17$ $-0.594$ $0.553$ Treatment interaction	Replicate variance	2.4 × 10	4.8 × 10		
N7NO Intercept $-0.619$ $0.121$ $-5.114$ <0.0001 Feeding treatments $-0.41$ $0.178$ $-2.296$ <0.05 <i>Wolbachia</i> treatments $0.058$ $0.17$ $0.341$ $0.733$ Treatment interaction $-0.182$ $0.254$ $-0.717$ $0.474$ Replicate variance $9.7 \times 10^{-15}$ $9.8 \times 10^{-8}$ w1118 Intercept $-0.518$ $0.119$ $-4.339$ <0.0001 Feeding treatments $-0.545$ $0.178$ $-3.062$ <0.01 <i>Wolbachia</i> treatments $-0.563$ $0.179$ $-3.154$ <0.01 Treatment interaction $0.649$ $0.257$ $2.522$ <0.05 Replicate variance $5.9 \times 10^{-12}$ $2.4 \times 10^{-6}$ w1118 Intercept $-0.504$ $0.119$ $-4.228$ <0.0001 Feeding treatments $-0.631$ $0.18$ $-3.51$ <0.001 <i>Wolbachia</i> treatments $-0.101$ $0.17$ $-0.594$ $0.553$ Treatment interaction $0.137$ $0.254$ $0.537$ $0.591$	component				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	N7NO				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Intercept	-0.619	0.121	-5.114	< 0.0001
	Feeding treatments	-0.41	0.178	-2.296	< 0.05
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Wolbachia treatments	0.058	0.17	0.341	0.733
Replicate variance component $9.7 \times 10^{-15}$ $9.8 \times 10^{-8}$ w1118Intercept $-0.518$ $0.119$ $-4.339$ $<0.0001$ Feeding treatments $-0.545$ $0.178$ $-3.062$ $<0.01$ Wolbachia treatments $-0.563$ $0.179$ $-3.154$ $<0.01$ Treatment interaction $0.649$ $0.257$ $2.522$ $<0.05$ Replicate variance component $5.9 \times 10^{-12}$ $2.4 \times 10^{-6}$ $w1118Intercept-0.5040.119-4.228<0.0001Feeding treatments-0.6310.18-3.51<0.001Wolbachia treatments-0.1010.17-0.5940.553Treatment interaction0.1370.2540.5370.591$	Treatment interaction	-0.182	0.254	-0.717	0.474
$\begin{array}{c} \mbox{component} \\ \mbox{w1118} \\ \mbox{Intercept} & -0.518 & 0.119 & -4.339 & <0.0001 \\ \mbox{Feeding treatments} & -0.545 & 0.178 & -3.062 & <0.01 \\ \mbox{Wolbachia treatments} & -0.563 & 0.179 & -3.154 & <0.01 \\ \mbox{Treatment interaction} & 0.649 & 0.257 & 2.522 & <0.05 \\ \mbox{Replicate variance} & 5.9 \times 10^{-12} & 2.4 \times 10^{-6} \\ \mbox{component} \\ \\ \mbox{w1118} \\ \mbox{Intercept} & -0.504 & 0.119 & -4.228 & <0.0001 \\ \mbox{Feeding treatments} & -0.631 & 0.18 & -3.51 & <0.001 \\ \mbox{Wolbachia treatments} & -0.101 & 0.17 & -0.594 & 0.553 \\ \mbox{Treatment interaction} & 0.137 & 0.254 & 0.537 & 0.591 \\ \end{array}$	Replicate variance	$9.7  imes 10^{-15}$	$9.8  imes 10^{-8}$		
	component				
with b       -0.518       0.119       -4.339       <0.0001	w1118				
Intercept       -0.516       0.117       -1.3062       <0.001	Intercept	-0.518	0.119	-4 339	< 0.0001
Weilbachia treatments $-0.543$ $0.170$ $-0.503$ $0.001$ Treatment interaction $0.649$ $0.257$ $2.522$ $<0.01$ Replicate variance $5.9 \times 10^{-12}$ $2.4 \times 10^{-6}$ $<0.01$ w1118       Intercept $-0.504$ $0.119$ $-4.228$ $<0.0001$ Feeding treatments $-0.631$ $0.18$ $-3.51$ $<0.001$ Wolbachia treatments $-0.101$ $0.17$ $-0.594$ $0.553$ Treatment interaction $0.137$ $0.254$ $0.537$ $0.591$	Feeding treatments	-0.545	0.178	-3.062	< 0.0001
Treatment interaction $0.649$ $0.257$ $2.522$ $<0.05$ Replicate variance component $5.9 \times 10^{-12}$ $2.4 \times 10^{-6}$ $2.522$ $<0.05$ w1118       Intercept $-0.504$ $0.119$ $-4.228$ $<0.001$ Feeding treatments $-0.631$ $0.18$ $-3.51$ $<0.001$ <i>Wolbachia</i> treatments $-0.101$ $0.17$ $-0.594$ $0.553$ Treatment interaction $0.137$ $0.254$ $0.537$ $0.591$	Wolhachia treatments	-0.563	0.179	-3.154	< 0.01
Replicate variance component $5.9 \times 10^{-12}$ $2.4 \times 10^{-6}$ $1000$ w1118       Intercept $-0.504$ $0.119$ $-4.228$ $<0.0001$ Feeding treatments $-0.631$ $0.18$ $-3.51$ $<0.001$ <i>Wolbachia</i> treatments $-0.101$ $0.17$ $-0.594$ $0.553$ Treatment interaction $0.137$ $0.254$ $0.537$ $0.591$	Treatment interaction	0.649	0.257	2.522	< 0.05
w1118     -0.504     0.119     -4.228     <0.0001       Feeding treatments     -0.631     0.18     -3.51     <0.001	Replicate variance	$5.9 \times 10^{-12}$	$2.4 \times 10^{-6}$	21022	10100
w1118       Intercept       -0.504       0.119       -4.228       <0.0001	component				
w1118         -0.504         0.119         -4.228         <0.001           Feeding treatments         -0.631         0.18         -3.51         <0.001	-				
Intercept         -0.504         0.119         -4.228         <0.001           Feeding treatments         -0.631         0.18         -3.51         <0.001	w1118				
Feeding treatments         -0.631         0.18         -3.51         <0.001           Wolbachia treatments         -0.101         0.17         -0.594         0.553           Treatment interaction         0.137         0.254         0.537         0.591	Intercept	-0.504	0.119	-4.228	< 0.0001
Wolbachia treatments         -0.101         0.17         -0.594         0.553           Treatment interaction         0.137         0.254         0.537         0.591	Feeding treatments	-0.631	0.18	-3.51	< 0.001
Treatment interaction 0.137 0.254 0.537 0.591	Wolbachia treatments	-0.101	0.17	-0.594	0.553
	Treatment interaction	0.137	0.254	0.537	0.591
Replicate variance 0 0	Replicate variance	0	0		

 TABLE 1 Analysis of mortality of *Drosophila* larvae in response to DCV in feed with or without *Wolbachia*<sup>a</sup>

<sup>a</sup> Generalized linear mixed-effects regression (GLMER) analysis of the percent mortality in five *Drosophila* lines in response to feeding treatment with PBS or DCV. Each *Drosophila* line was either coinfected with a *Wolbachia* strain (wAu, wRi, wNo, wMelPop, or wMel) or was not exposed to *Wolbachia* (*-wol*). Treatment interaction is a comparison of percent mortality across all combinations of feeding treatment (DCV or PBS) and the presence/absence of *Wolbachia*.

protective in larvae and what controls the differences in density between larvae and adults. The finding that *Wolbachia*-protection correlates with *Wolbachia* density is consistent with previous findings in adult flies following a systemic infection (29–32). Gradually reducing *Wolbachia* density in both *Drosophila* adults and mosquito cell culture using tetracycline leads to a dose-dependent loss of antiviral protection (12, 30).

*Wolbachia*-mediated antiviral protection is not limited to *Drosophila*, and since *Wolbachia* infects up to 40% of all arthropod species (35) it may be important to consider the impact of life-stage susceptibility on arthropod population dynamics and viral transmission. Similarly to *Drosophila*, mosquitoes also undergo metamorphosis, a change that can result in life-stage-dependent

differences in viral susceptibility. Mosquitoes are known to form natural associations with Wolbachia; however, it is artificial Wolbachia transinfections that have shown promise as a tool for limiting spread of human pathogenic viruses (5, 6). Commonly, there is a focus on transmission of arboviruses that occurs between mosquitoes and human hosts. While this horizontal transmission is responsible for the major health concerns in humans, vertical transmission of arboviruses within mosquito populations can affect the maintenance of the virus within the population (64, 65). Viruses such as dengue virus and Chikungunya virus can be vertically transmitted from an infected adult female to its offspring. Dengue virus can spread vertically under both natural (66-69) and laboratory conditions (70-72). Furthermore, transovarially infected female mosquitoes can transmit dengue virus orally (73). Chikungunya is also capable of vertical transmission under laboratory conditions, which would suggest that similar transmission is possible in nature (64).

Various models have been applied to try to understand the impact of *Wolbachia* on the transmission of dengue virus in its mosquito host (74–76). These models do not consider the effects of vertical transmission on the maintenance of dengue virus within a population, which has been suggested to be an important factor affecting the ability of the virus to persist within the population in rural areas with low human population densities (65). Furthermore, vertical transmission could allow the survival of ar-



**FIG 3** The densities of six different *Wolbachia* strains during larval and adult stages of development. (A) Relative abundance of the *Wolbachia* surface protein gene (*wsp*) in *D. melanogaster*, using *RpL32* as the reference gene. (B) Relative abundance of the *wsp* gene in *D. simulans*, using *Act5C* as the reference gene.

boviruses during adverse climatic conditions and has been suggested to be an important mechanism of maintenance of the virus during interepidemic periods (64). Given the importance of vertical transmission on virus dynamics and the possible life-stagedependent variations in *Wolbachia*-mediated protection, it is important to consider the impact of *Wolbachia* antiviral protection, or the lack of thereof, on the maintenance of a virus within a population. Understanding the impact of *Wolbachia* antiviral protection at different insect life stages is likely to be an important consideration when designing programs to minimize the spread of insect-borne viruses.

# ACKNOWLEDGMENTS

We thank David Merritt and members of the Johnson lab for useful comments, and we thank Craig White for help with the statistical analysis.

#### REFERENCES

- 1. Johnson KN. 2015. Bacteria and antiviral immunity in insects. Curr Opin Insect Sci 8:97–103. http://dx.doi.org/10.1016/j.cois.2015.01.008.
- Hedges LM, Brownlie JC, O'Neill SL, Johnson KN. 2008. Wolbachia and virus protection in insects. Science 322:702. http://dx.doi.org/10.1126 /science.1162418.
- Teixeira L, Ferreira A, Ashburner M. 2008. The bacterial symbiont Wolbachia induces resistance to RNA viral infections in Drosophila melanogaster. PLoS Biol 6:e1000002. http://dx.doi.org/10.1371/journal.pbio .1000002.
- Brownlie JC, Johnson KN. 2009. Symbiont-mediated protection in insect hosts. Trends Microbiol 17:348–354. http://dx.doi.org/10.1016 /j.tim.2009.05.005.
- Rainey SM, Shah P, Kohl A, Dietrich I. 2014. Understanding the Wolbachia-mediated inhibition of arboviruses in mosquitoes: progress and challenges. J Gen Virol 95:517–530. http://dx.doi.org/10.1099/vir.0.057422-0.
- Bourtzis K, Dobson SL, Xi ZY, Rasgon JL, Calvitti M, Moreira LA, Bossin HC, Moretti R, Baton LA, Hughes GL, Mavingui P, Gilles JRL. 2014. Harnessing mosquito-*Wolbachia* symbiosis for vector and disease control. Acta Trop 132:S150–S163. http://dx.doi.org/10.1016/j.actatropica .2013.11.004.
- Moreira LA, Iturbe-Ormaetxe I, Jeffery JA, Lu GJ, Pyke AT, Hedges LM, Rocha BC, Hall-Mendelin S, Day A, Riegler M, Hugo LE, Johnson KN, Kay BH, McGraw EA, van den Hurk AF, Ryan PA, O'Neill SL. 2009. A *Wolbachia* symbiont in *Aedes aegypti* limits infection with dengue, Chikungunya, and plasmodium. Cell 139:1268–1278. http://dx.doi.org /10.1016/j.cell.2009.11.042.
- 8. Blagrove MSC, Arias-Goeta C, Failloux AB, Sinkins SP. 2012. *Wolbachia* strain *w*Mel induces cytoplasmic incompatibility and blocks dengue transmission in *Aedes albopictus*. Proc Natl Acad Sci U S A **109**:255–260. http://dx.doi.org/10.1073/pnas.1112021108.
- Bian GW, Xu Y, Lu P, Xie Y, Xi ZY. 2010. The endosymbiotic bacterium Wolbachia induces resistance to dengue virus in Aedes aegypti. PLoS Pathog 6:e1000833. http://dx.doi.org/10.1371/journal.ppat.1000833.
- Frentiu FD, Zakir T, Walker T, Popovici J, Pyke AT, van den Hurk A, McGraw EA, O'Neill SL. 2014. Limited dengue virus replication in fieldcollected *Aedes aegypti* mosquitoes infected with *Wolbachia*. PLoS Negl Trop Dis 8:e2688. http://dx.doi.org/10.1371/journal.pntd.0002688.
- Rances E, Ye YXH, Woolfit M, McGraw EA, O'Neill SL. 2012. The relative importance of innate immune priming in *Wolbachia*-mediated dengue interference. PLoS Pathog 8:e1002548. http://dx.doi.org/10.1371 /journal.ppat.1002548.
- Lu P, Bian GW, Pan XL, Xi ZY. 2012. Wolbachia induces densitydependent inhibition to dengue virus in mosquito cells. PLoS Negl Trop Dis 6:e1754. http://dx.doi.org/10.1371/journal.pntd.0001754.
- Walker T, Johnson PH, Moreira LA, Iturbe-Ormaetxe I, Frentiu FD, McMeniman CJ, Leong YS, Dong Y, Axford J, Kriesner P, Lloyd AL, Ritchie SA, O'Neill SL, Hoffmann AA. 2011. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature 476: 450–453. http://dx.doi.org/10.1038/nature10355.
- 14. Hoffmann AA, Montgomery BL, Popovici J, Iturbe-Ormaetxe I, Johnson PH, Muzzi F, Greenfield M, Durkan M, Leong YS, Dong Y, Cook

H, Axford J, Callahan AG, Kenny N, Omodei C, McGraw EA, Ryan PA, Ritchie SA, Turelli M, O'Neill SL. 2011. Successful establishment of *Wolbachia* in *Aedes* populations to suppress dengue transmission. Nature 476:454–457. http://dx.doi.org/10.1038/nature10356.

- Blagrove MSC, Arias-Goeta C, Di Genua C, Failloux AB, Sinkins SP. 2013. A Wolbachia wMel transinfection in Aedes albopictus is not detrimental to host fitness and inhibits Chikungunya virus. PLoS Negl Trop Dis 7:e2152. http://dx.doi.org/10.1371/journal.pntd.0002152.
- Mousson L, Martin E, Zouache K, Madec Y, Mavingui P, Failloux AB. 2010. Wolbachia modulates Chikungunya replication in Aedes albopictus. Mol Ecol 19:1953–1964. http://dx.doi.org/10.1111/j.1365-294X.2010 .04606.x.
- van den Hurk AF, Hall-Mendelin S, Pyke AT, Frentiu FD, McElroy K, Day A, Higgs S, O'Neill SL. 2012. Impact of *Wolbachia* on infection with Chikungunya and yellow fever viruses in the mosquito vector *Aedes aegypti*. PLoS Negl Trop Dis 6:e1892. http://dx.doi.org/10.1371/journal .pntd.0001892.
- Żele F, Nicot A, Berthomieu A, Weill M, Duron O, Rivero A. 2014. Wolbachia increases susceptibility to Plasmodium infection in a natural system. Proc R Soc B 281:20132837. http://dx.doi.org/10.1098/rspb.2013 .2837.
- Graham RI, Grzywacz D, Mushobozi WL, Wilson K. 2012. Wolbachia in a major African crop pest increases susceptibility to viral disease rather than protects. Ecol Lett 15:993–1000. http://dx.doi.org/10.1111/j.1461 -0248.2012.01820.x.
- Dodson BL, Hughes GL, Paul O, Matacchiero AC, Kramer LD, Rasgon JL. 2014. Wolbachia enhances West Nile Virus (WNV) infection in the mosquito Culex tarsalis. PLoS Negl Trop Dis 8:e2965. http://dx.doi.org/10 .1371/journal.pntd.0002965.
- Hughes GL, Vega-Rodriguez J, Xue P, Rasgon JL. 2012. Wolbachia strain wAlbB enhances infection by the rodent malaria parasite *Plasmodium berghei* in *Anopheles gambiae* mosquitoes. Appl Environ Microbiol 78:1491– 1495. http://dx.doi.org/10.1128/AEM.06751-11.
- 22. Baton LA, Pacidonio EC, Goncalves DD, Moreira LA. 2013. *wFlu:* characterization and evaluation of a native *Wolbachia* from the mosquito *Aedes fluviatilis* as a potential vector control agent. PLoS One 8:e59619. http://dx.doi.org/10.1371/journal.pone.0059619.
- 23. Murdock CC, Blanford S, Hughes GL, Rasgon JL, Thomas MB. 2014. Temperature alters Plasmodium blocking by *Wolbachia*. Sci Rep 4:3932. http://dx.doi.org/10.1038/srep03932.
- Hussain M, Frentiu FD, Moreira LA, O'Neill SL, Asgari S. 2011. Wolbachia uses host microRNAs to manipulate host gene expression and facilitate colonization of the dengue vector Aedes aegypti. Proc Natl Acad Sci U S A 108:9250–9255. http://dx.doi.org/10.1073/pnas.1105469108.
- Zhang GM, Hussain M, O'Neill SL, Asgari S. 2013. Wolbachia uses a host microRNA to regulate transcripts of a methyltransferase, contributing to dengue virus inhibition in *Aedes aegypti*. Proc Natl Acad Sci U S A 110: 10276–10281. http://dx.doi.org/10.1073/pnas.1303603110.
- Caragata EP, Rances E, Hedges LM, Gofton AW, Johnson KN, O'Neill SL, McGraw EA. 2013. Dietary cholesterol modulates pathogen blocking by *Wolbachia*. PLoS Pathog 9:e1003459. http://dx.doi.org/10.1371/journal .ppat.1003459.
- Pan XL, Zhou GL, Wu JH, Bian GW, Lu P, Raikhel AS, Xi ZY. 2012. Wolbachia induces reactive oxygen species (ROS)-dependent activation of the Toll pathway to control dengue virus in the mosquito Aedes aegypti. Proc Natl Acad Sci U S A 109:E23–E31. http://dx.doi.org/10.1073/pnas .1116932108.
- Wong ZS, Brownlie JC, Johnson KN. 2015. Oxidative stress correlates with *Wolbachia*-mediated antiviral protection in *Wolbachia-Drosophila* associations. Appl Environ Microbiol 81:3001–3005. http://dx.doi.org/10 .1128/AEM.03847-14.
- Osborne SE, Leong YS, O'Neill SL, Johnson KN. 2009. Variation in antiviral protection mediated by different *Wolbachia* strains in *Drosophila simulans*. PLoS Pathog 5:e1000656. http://dx.doi.org/10.1371/journal .ppat.1000656.
- Osborne SE, Iturbe-Ormaetxe I, Brownlie JC, O'Neill SL, Johnson KN. 2012. Antiviral protection and the importance of *Wolbachia* density and tissue tropism in *Drosophila simulans*. Appl Environ Microbiol 78:6922– 6929. http://dx.doi.org/10.1128/AEM.01727-12.
- 31. Chrostek E, Marialva MSP, Esteves SS, Weinert LA, Martinez J, Jiggins FM, Teixeira L. 2013. Wolbachia variants induce differential protection to viruses in Drosophila melanogaster: a phenotypic and phy-

logenomic analysis. PLoS Genet 9:e1003896. http://dx.doi.org/10.1371 /journal.pgen.1003896.

- Martinez J, Longdon B, Bauer S, Chan YS, Miller WJ, Bourtzis K, Teixeira L, Jiggins FM. 2014. Symbionts commonly provide broad spectrum resistance to viruses in insects: a comparative analysis of *Wolbachia* strains. PLoS Pathog 10:e1004369. http://dx.doi.org/10.1371/journal.ppat .1004369.
- 33. Bian GW, Zhou GL, Lu P, Xi ZY. 2013. Replacing a native *Wolbachia* with a novel strain results in an increase in endosymbiont load and resistance to dengue virus in a mosquito vector. PLoS Negl Trop Dis 7:e2250. http://dx.doi.org/10.1371/journal.pntd.0002250.
- Frentiu FD, Robinson J, Young PR, McGraw EA, O'Neill SL. 2010. Wolbachia-mediated resistance to dengue virus infection and death at the cellular level. PLoS One 5:e13398. http://dx.doi.org/10.1371/journal.pone .0013398.
- 35. Zug R, Hammerstein P. 2012. Still a host of hosts for *Wolbachia*: analysis of recent data suggests that 40% of terrestrial arthropod species are infected. PLoS One 7:e38544. http://dx.doi.org/10.1371 /journal.pone.0038544.
- Stevanovic A, Johnson KN. 2015. Infectivity of Drosophila C virus following oral delivery in *Drosophila* larvae. J Gen Virol 96:1490–1496. http: //dx.doi.org/10.1099/vir.0.000068.
- Ferreira AG, Naylor H, Esteves SS, Pais IS, Martins NE, Teixeira L. 2014. The Toll-dorsal pathway is required for resistance to viral oral infection in *Drosophila*. PLoS Pathog 10:e1004507. http://dx.doi.org/10 .1371/journal.ppat.1004507.
- Xu J, Hopkins K, Sabin L, Yasunaga A, Subramanian H, Lamborn I, Gordesky-Gold B, Cherry S. 2013. ERK signaling couples nutrient status to antiviral defense in the insect gut. Proc Natl Acad Sci U S A 110:15025– 15030. http://dx.doi.org/10.1073/pnas.1303193110.
- Huszart T, Imler JL. 2008. Drosophila viruses and the study of antiviral host-defense. Adv Virus Res 72:227–265. http://dx.doi.org/10.1016/S0065 -3527(08)00406-5.
- 40. Johnson KN, Christian PD. 1998. The novel genome organization of the insect picorna-like virus Drosophila C virus suggests this virus belongs to a previously undescribed virus family. J Gen Virol **79**:191–203. http://dx .doi.org/10.1099/0022-1317-79-1-191.
- 41. Jousset FX, Plus N, Croizier G, Thomas M. 1972. Existence in *Drosophila* of 2 groups of picornavirus of different serological and biological properties. C R Acad Sci Hebd Seances Acad Sci D 275:3043–3046. (In French.)
- Gomariz-Zilber E, Jeune B, Thomas-Orillard M. 1998. Limiting conditions of the horizontal transmission of the Drosophila C virus in its host (*D. melanogaster*). Acta Oecol 19:125–137. http://dx.doi.org/10.1016 /S1146-609X(98)80016-7.
- Bainbridge SP, Bownes M. 1981. Staging the metamorphosis of Drosophila melanogaster. J Embryol Exp Morphol 66:57-80.
- 44. White KP, Rifkin SA, Hurban P, Hogness DS. 1999. Microarray analysis of *Drosophila* development during metamorphosis. Science 286:2179–2184. http://dx.doi.org/10.1126/science.286.5447.2179.
- Briggs CJ, Godfray HCJ. 1995. The dynamics of insect-pathogen interactions in stage-structured populations. Am Nat 145:855–887. http://dx .doi.org/10.1086/285774.
- Bernal A, Simon O, Williams T, Caballero P. 2014. Stage-specific insecticidal characteristics of a nucleopolyhedrovirus isolate from Chrysodeixis chalcites enhanced by optical brighteners. Pest Manag Sci 70:798–804. http://dx.doi.org/10.1002/ps.3617.
- McNeil J, Cox-Foster D, Gardner M, Slavicek J, Thiem S, Hoover K. 2010. Pathogenesis of *Lymantria dispar* multiple nucleopolyhedrovirus in *L. dispar* and mechanisms of developmental resistance. J Gen Virol 91: 1590–1600. http://dx.doi.org/10.1099/vir.0.018952-0.
- Milks ML. 1997. Comparative biology and susceptibility of cabbage looper (Lepidoptera: Noctuidae) lines to a nuclear polyhedrosis virus. Environ Entomol 26:839–848. http://dx.doi.org/10.1093/ee/26.4.839.
- Hedges LM, Johnson KN. 2008. Induction of host defence responses by Drosophila C virus. J Gen Virol 89:1497–1501. http://dx.doi.org/10.1099 /vir.0.83684-0.
- Johnson KN, Christian PD. 1999. Molecular characterization of Drosophila C virus isolates. J Invertebr Pathol 73:248–254. http://dx.doi.org /10.1006/jipa.1998.4830.
- Schneider I. 1972. Cell lines derived from late embryonic stages of *Drosophila melanogaster*. J Embryol Exp Morphol 27:353–365.
- 52. Muller PY, Janovjak H, Miserez AR, Dobbie Z. 2002. Processing of gene

expression data generated by quantitative real-time RT-PCR. Biotechniques 32:1372–1379.

- 53. Bates D, Mäechler M, Bolker B, Walker S, Christensen RHB, Singmann H, Dai B, Grothendieck G. 2014. lme4: linear mixed-effects models using Eigen and S4. R package version 1.1-7. R Foundation for Statistical Computing, Vienna, Austria. http://cran.r-project.org/package=lme4.
- Lemaitre B, Meister M, Govind S, Georgel P, Steward R, Reichhart JM, Hoffmann JA. 1995. Functional-analysis and regulation of nuclear import of Dorsal during the immune-response in *Drosophila*. EMBO J 14:536–545.
- 55. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. 1996. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in *Drosophila* adults. Cell 86:973–983. http: //dx.doi.org/10.1016/S0092-8674(00)80172-5.
- Kylsten P, Samakovlis C, Hultmark D. 1990. The cecropin locus in Drosophila: a compact gene-cluster involved in the response to infection. EMBO J 9:217–224.
- 57. Wicker C, Reichhart JM, Hoffmann D, Hultmark D, Samakovlis C, Hoffmann JA. 1990. Characterization of a *Drosophila* cDNA-encoding a novel member of the diptericin family of immune peptides. J Biol Chem 265:22493–22498.
- Bosco-Drayon V, Poidevin M, Boneca IG, Narbonne-Reveau K, Royet J, Charroux B. 2012. Peptidoglycan sensing by the receptor PGRP-LE in the *Drosophila* gut induces immune responses to infectious bacteria and tolerance to microbiota. Cell Host Microbe 12:153–165. http://dx.doi.org /10.1016/j.chom.2012.06.002.
- 59. Vodovar N, Vinals M, Liehl P, Basset A, Degrouard J, Spellman P, Boccard F, Lemaitre B. 2005. *Drosophila* host defense after oral infection by an entomopathogenic *Pseudomonas* species. Proc Natl Acad Sci U S A 102:11414–11419. http://dx.doi.org/10.1073/pnas.0502240102.
- Buchon N, Broderick NA, Poidevin M, Pradervand S, Lemaitre B. 2009. Drosophila intestinal response to bacterial infection: activation of host defense and stem cell proliferation. Cell Host Microbe 5:200–211. http: //dx.doi.org/10.1016/j.chom.2009.01.003.
- McGraw EA, Merritt DJ, Droller JN, O'Neill SL. 2002. Wolbachia density and virulence attenuation after transfer into a novel host. Proc Natl Acad Sci U S A 99:2918–2923. http://dx.doi.org/10.1073/pnas.052466499.
- Chrostek E, Teixeira L. 2015. Mutualism breakdown by amplification of *Wolbachia* genes. PLoS Biol 13:e1002065. http://dx.doi.org/10.1371 /journal.pbio.1002065.
- Min KT, Benzer S. 1997. Wolbachia, normally a symbiont of Drosophila, can be virulent, causing degeneration and early death. Proc Natl Acad Sci U S A 94:10792–10796. http://dx.doi.org/10.1073/pnas.94.20.10792.
- 64. Agarwal A, Dash PK, Singh AK, Sharma S, Gopalan N, Rao PVL, Parida MM, Reiter P. 2014. Evidence of experimental vertical transmission of emerging novel ECSA genotype of Chikungunya virus in *Aedes aegypti*. PLoS Negl Trop Dis 8:e2990. http://dx.doi.org/10.1371/journal.pntd.0002990.
- Esteva L, Vargas C. 2000. Influence of vertical and mechanical transmission on the dynamics of dengue disease. Math Biosci 167:51–64. http://dx .doi.org/10.1016/S0025-5564(00)00024-9.
- 66. Thongrungkiat S, Maneekan P, Wasinpiyamongkol L, Prummongkol S. 2011. Prospective field study of transovarial dengue-virus transmission by two different forms of *Aedes aegypti* in an urban area of Bangkok, Thailand. J Vector Ecol 36:147–152. http://dx.doi.org/10.1111/j.1948-7134.2011.00151.x.
- 67. Khin MM, Than KA. 1983. Trans-ovarial transmission of dengue-2 virus by *Aedes aegypti* in nature. Am J Trop Med Hyg **32**:590–594.
- Fouque F, Garinci R, Gaborit P. 2004. Epidemiological and entomological surveillance of the co-circulation of DEN-I, DEN-2 and DEN-4 viruses in French Guiana. Trop Med Int Health 9:41–46. http://dx.doi.org /10.1046/j.1365-3156.2003.01166.x.
- Gunther J, Martinez-Munoz JP, Perez-Ishiwara DG, Salas-Benito J. 2007. Evidence of vertical transmission of dengue virus in two endemic localities in the state of Oaxaca, Mexico. Intervirology 50:347–352. http: //dx.doi.org/10.1159/000107272.
- Joshi V, Mourya DT, Sharma RC. 2002. Persistence of dengue-3 virus through transovarial transmission passage in successive generations of *Aedes aegypti* mosquitoes. Am J Trop Med Hyg 67:158–161.
- 71. Rosen L. 1987. Sexual transmission of dengue viruses by *Aedes albopictus*. Am J Trop Med Hyg **37**:398–402.
- Buckner EA, Alto BW, Lounibos LP. 2013. Vertical transmission of Key West dengue-1 virus by *Aedes aegypti* and *Aedes albopictus* (Diptera: Culicidae) mosquitoes from Florida. J Med Entomol 50:1291–1297. http: //dx.doi.org/10.1603/ME13047.

- 73. Mourya DT, Gokhale MD, Basu A, Barde PV, Sapkal GN, Padbidri VS, Gore MM. 2001. Horizontal and vertical transmission of dengue virus type 2 in highly and lowly susceptible strains of *Aedes aegypti* mosquitoes. Acta Virol 45:67–71.
- Hughes H, Britton NF. 2013. Modelling the use of *Wolbachia* to control dengue fever transmission. Bull Math Biol 75:796–818. http://dx.doi.org /10.1007/s11538-013-9835-4.
- Ndii MZ, Hickson RI, Mercer GN. 2012. Modelling the introduction of *Wolbachia* into *Aedes aegypti* mosquitoes to reduce dengue transmission. ANZIAM J 53:213–227. http://dx.doi.org/10.1017/S1446181112 000132.
- Ndii MZ, Hickson RI, Allingham D, Mercer GN. 2015. Modelling the transmission dynamics of dengue in the presence of *Wolbachia*. Math Biosci 262:157–166. http://dx.doi.org/10.1016/j.mbs.2014.12.011.